Citius Oncology shares surge 31.22% intraday following strong LYMPHIR commercial adoption and clinical progress updates.

Citius Oncology, Inc. surged 31.22% intraday following the release of a commercial update highlighting strong early adoption metrics for LYMPHIR, its FDA-approved treatment for cutaneous T-cell lymphoma. The company reported 83% of target accounts had added or were progressing LYMPHIR through formulary review, along with broad payer coverage across 135 health plans and no reimbursement barriers. Positive early clinical data from investigator-led trials, including an 86% response rate in a Phase 1 trial with LYMPHIR administered before CAR-T therapy, further reinforced the drug’s commercial and clinical potential. The news signaled robust market access, increasing demand for clinical education, and expansion into community settings, driving optimism among investors about LYMPHIR’s growth trajectory and long-term value.